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CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Prognosis of follicular lymphoma: a predictive model based
on a retrospective analysis of 987 cases
Massimo Federico, Umberto Vitolo, Pier Luigi Zinzani, Teodoro Chisesi, Vera Clo`, Giampiero Bellesi, Massimo Magagnoli, Marina Liberati,
Carola Boccomini, Pasquale Niscola, Vincenzo Pavone, Antonio Cuneo, Gino Santini, Maura Brugiatelli, Luca Baldini, Luigi Rigacci,
and Luigi Resegotti, for the Intergruppo Italiano Linfomi
Patients (n-987) with a histologically con-
firmed diagnosis of follicular lymphoma
were studied with the aim of developing a
prognostic model specifically devised for
this type of lymphoma. We collected
information on age, sex, Ann Arbor stage,
number of extranodal disease sites, bone
marrow (BM) involvement, bulky disease,
B symptom criteria (fever, night sweats,
and weight loss), performance status
(PS), serum lactate dehydrogenase (LDH)
level, serum albumin level, hemoglobin
level, and erythrocyte sedimentation rate
(ESR). In the training sample of 429
patients with complete data, multivariate
analysis showed that age, sex, number of
extranodal sites, B symptoms, serum
LDH level, and ESR were factors predic-
tive for overall survival. Using these 6
variables, a prognostic model was de-
vised to identify 3 groups at different risk.
The 5- and 10-year survival rate was 90%
and 65% for patients at low risk, respec-
tively; 75% and 54% for patients at
intermediate risk; and 38% and 11% for
those at high risk (log-rank test, 86.62;
P F .0001). The model was also predic-
tive (P 5 .0001) in the validation sample
of 265 patients with complete data only
for the 6 variables used in the develop-
ment of the model and even in the group
of 210 patients from the validation sample
uniformly treated with doxorubicin-con-
taining regimens (P 5 .0001). The prog-
nostic model appears to be very useful in
identifying patients with follicular lym-
phoma at low, intermediate, or high risk.
(Blood. 2000;95:783-789)
r 2000 by The American Society of Hematology
Introduction
Follicular lymphoma is the most frequent subtype of malignant
lymphoma in western countries and accounts for approximately
25% of all adult non-Hodgkin’s lymphoma.1 Before the advent of
chemotherapy, the majority of patients with follicular lymphoma
died within 5 years. With current therapy the expected median
survival is approximately 8-10 years.2 The management of these
patients is one of the most controversial issues in oncology. A
variety of treatment approaches, including the use of single
alkylating agents, combination chemotherapy with or without
doxorubicin, total lymphoid irradiation, and a combination of
chemo-radiotherapy, have been applied to these patients. With
current treatment options, complete remission rates range from
65% to 85%. Despite these attempts, in the last 2 decades overall
survival was not significantly influenced by different therapies.3-7
Sometimes patients over 60 years of age and asymptomatic at
diagnosis can defer treatment until signs of disease progression
appear, and many patients do not require treatment for a number of
years. In randomized trials,8,9 the long-term survival of these
patients was similar to the survival of patients treated immediately
at time of diagnosis.
Although patients with follicular lymphoma have relatively
long median survival times and exhibit dramatic responses to initial
therapy, they should be considered affected by a fatal malignancy.
Patients tend to relapse over time, their response to salvage therapy
is of shorter duration after every relapse, and they eventually die of
disease-related causes. Finally, a small but significant group of
patients with follicular lymphoma survive a relatively short time.
Although it is difficult to identify high-risk and low-risk patients at
diagnosis, it would be helpful to select those patients who are
suitable for experimental therapy and those patients who should
avoid undue therapy-related toxicity. In patients with follicular
lymphoma, a variety of prognostic factors have been found
including age, stage, tumor burden, bone marrow (BM) involve-
ment, B symptoms, performance status (PS), serum lactate dehydro-
genase (LDH) level, anemia, erythrocyte sedimentation rate (ESR),
and beta-2 microglobulin.10-14 More recently the International
Prognostic Index (IPI)15 and other predictive models have been
applied to low-grade lymphomas with conflicting results.16-19
To assess the reproducibility of the IPI and to develop, if
possible, a prognostic model specifically devised for follicular
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lymphoma, the Intergruppo Italiano Linfomi (Italian Lymphoma
Intergroup) prompted a collaborative study. Here we present the
results of this study performed on 987 patients treated at cooperat-
ing centers between 1985 and 1996.
Methods
Eligibility criteria
We considered eligible for this study all patients with a histologically
confirmed diagnosis of follicular lymphoma, including follicular large-cell
lymphoma, according to updated Kiel classification, who were either
enrolled in prospective clinical trials between 1985 and 1996 or treated at
participating centers according to specified guidelines. Initial diagnosis was
not revised, and thus the grading of follicular lymphoma was not assessed.
A total of 1096 patients from 8 single centers and 2 cooperative groups were
merged into a preliminary working file. We excluded 109 patients from the
study for the following reasons: revised histology, 12 patients; incomplete
data, 30 patients; inadequate follow-up, 67 patients. Finally, 987 patients
were included in the analysis. We collected information on those parameters
that were already known to be of prognostic relevance and were available
for almost all patients: age, sex, Ann Arbor stage, number of extranodal
disease sites, BM involvement, B symptoms, bulky disease, PS, serum
LDH level, serum albumin level, hemoglobin level, and ESR. Separation
levels, based on the following, formed the 2 most distinct populations at risk
in terms of survival: albumin less than or equal to 30 mmol/L, ESR greater
than 30 mm, and hemoglobin less than 120 mmol/L for men and less than
100 mmol/L for women. These levels were used for subsequent analyses. In
addition to other extralymphatic tissues, we recorded BM and spleen as
sites of extranodal involvement. For the purpose of this study, peripheral
blood involvement was not recorded. Bulky disease was defined as a mass
with the largest dimension greater than or equal to 10 cm or, for the
mediastinum only, as a mass larger than one-third of the chest diameter.
According to Ann Arbor criteria, B symptoms were defined as recurrent
fever (more than 38°C), night sweats, or the loss of more than 10% of body
weight. Serum b2-microglobulin measurement was not routinely assessed.
Moreover, due to the retrospective essence of the study, not all variables
were available for each patient.
All patients were clinically staged. The extent of the disease was deter-
mined by a standardized staging evaluation that included chest and abdomen
computed tomography and BM biopsy. Response to treatment was assessed
1 month after the end of induction therapy by performing all examinations
necessary to control abnormal findings present at the time of diagnosis.
Complete remission (CR) was defined as the disappearance of all
clinical evidence of the disease and the normalization of all laboratory
values and radiographs that had been considered abnormal before starting
treatment, including a normalization of BM, if initially involved. Moreover,
patients who achieved a CR during therapy, but relapsed within 30 days
after therapy had been completed, were classified as nonresponders. Partial
remission (PR) was defined as a greater than 50% reduction in the largest
dimension of each anatomic site of measurable disease for at least 1 month.
No response (NR) was defined as a less than 50% regression or stable or
progressive disease. All early deaths due to disease progression or
treatment-related toxicity were considered as treatment failures, and
included in the NR group. All evaluations of clinical stage and response to
treatment were based on the original data recorded by local physicians.
Treatment strategies
Patients received a variety of treatment strategies: 75 patients (7.6%) were
treated with radiotherapy alone or received no initial treatment according to
the watch and wait strategy; 122 patients (12.4%) were treated with a single
agent either with or without a-interferon (IFN-a); 128 patients (13.0%)
were treated with CVP20 (cyclophosphamide, vincristine, and prednisolone)
or CVP-like regimens; 633 patients (64.1%) were treated with CHOP21
(cyclophosphamide, hydroxyldaunomycin, vincristine [Oncovin], and pred-
nisone) or other doxorubicin-containing regimens; and 29 patients (2.9%)
were treated with a variety of different approaches.
Statistical analysis
All data were analyzed with the Statistical Package for the Social Sciences
(SPSS).22 Differences in patient characteristics, response rates, and treat-
ment failures among groups were analyzed by the Fisher’s exact test for
contingency tables. Survival, relapse-free survival (RFS), and failure-free
survival (FFS) curves were estimated by the method of Kaplan-Meier. The
date of therapy initiation was not available in some cases, thus the survival
was calculated from the date of diagnosis until death from any cause. However,
the mean interval between the date of diagnosis and the start of therapy in
patients with complete data was 26 days. RFS was applied only to patients
in CR and was calculated from the end of induction therapy to the first
evidence of relapse. FFS was calculated for all patients and was measured
from the beginning of therapy to the time of disease progression (date of
assessment of response for patients with less than PR; date of start of second-
line therapy for patients with PR), relapse (for patients in CR), or death. The
log-rank test was used to assess the significance of differences in survival
for each prognostic factor. Cox proportional hazards regression model was
used in multivariate analysis to determine whether the identified risk factors
independently influenced survival rate. The limit of significance for all
analyses was defined as P 5 .05. Two-sided tests were used in all calculations.
Results
Analysis of response
Table 1 summarizes the characteristics of 987 patients eligible for
the study. With induction therapy, 65% of patients achieved a CR and
24% achieved a PR, with an overall response rate of 89%. Significant
correlations were observed between CR rate and the following: age
(P 5 .0073); sex (P 5 .0025); Ann Arbor stage (P , .0001); B symp-
toms (P 5 .0004); number of extranodal sites (P 5 .0275); perfor-
mance status (P 5 .0003); BM involvement (P , .0001); serum
LDH (P , .0001); hemoglobin (P , 5 .0001);and ESR (P 5 .0067).
Analysis of survival
After a median follow-up of 51 months (54 months for patients still
alive), 224 patients had died, and 763 were alive. The 5- and
10-year overall survival rates were 77% and 57%, respectively, and
a plateau had not been reached at time of analysis (Figure 1). The
5-year and 10-year RFS among patients who achieved CR was 62%
and 43%, respectively, and the 5-year and 10-year FFS was 48%
and 30%, respectively. The median FFS time was 54 months (95%
confidence intervals [CI], 46-62 months).
In univariate analysis of survival, poorer prognosis was associ-
ated with the following (Table 2): age greater than 60 years
(P , .0001); male sex (P 5 .0025); advanced stage (P , .0001);
the presence of B symptoms (P , .0001); the involvement of more
than 1 extranodal site (P 5 .0275); low performance status
(P , .0001); BM involvement (P 5 .0001); serum LDH level
above the upper normal limit (P 5 .0002), low serum albumin
level (P 5 .0086); low hemoglobin level (P 5 .0001); and high
ESR (P , .0001). The international prognostic index proved to be
of highly significant prognostic value (P , .0001).
Training sample
Information on the above-mentioned prognostic factors was not avail-
able in all cases: for example, staging information was available for
984 patients, whereas serum albumin levels were available only for
673 patients. Information on all 11 prognostic factors significantly
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associated with outcome in univariate analysis was complete for
429 patients. These 429 patients were selected as a training sample
in which to identify independent factors necessary to construct a
prognostic model.
The six characteristics that remained independently significant
in the analysis of the training sample were sex, age, B symptoms,
number of extranodal sites, serum LDH, and ESR (Table 3). Since
the relative risk associated with each of the 6 factors was
comparable, we constructed a risk score, simply summing the
number of risk factors present in a single patient at time of
diagnosis. There were no cases presenting all 6 adverse factors,
thus only 6 categories (score 0 through 5) were initially detected
(Table 4). Using the same methodology adopted for the construc-
tion of the international prognostic index for aggressive non-
Hodgkin’s lymphoma, risk groups were defined by comparing the
relative risk of death in patients with each possible number of
presenting risk factors and combining categories with similar
relative risk.15 Patients with similar relative risk were subsequently
stratified in 3 risk groups: score 0-1, low risk; score 2, intermediate
risk; score 3-5, high risk. The survival curves for the 3 risk groups
are shown in Figure 2A. The 5- and 10-year survival rates were
90% and 65%, respectively, for 274 patients at low risk; 75% and
54% for 97 patients at intermediate risk; and 38% and 11% for 57
patients at high risk (log-rank test, 86.62; P , .0001). The 5-year
RFS of patients in CR after initial therapy was 65% for patients at
low risk, 63% for patients at intermediate risk, and 51% for patients
Figure 1. Survival of all 987 patients with FL.
Table 1. Characteristics of patients
Characteristic No. of Cases %
Age
No more than 60 years 599 61
Greater than 60 years 388 39
Sex
Female 521 53
Male 466 47
Ann Arbor stage
I-II 250 25
III-IV 737 75
No. of extranodal sites
0-1 933 95
At least 2 54 5
BM involvement (959)
Absent 461 48
Present 498 52
Bulky disease (937)
Absent 819 87
Present 118 13
B Symptoms (980)
Absent 832 85
Present 148 15
Performance status (ECOG) (762)
0-1 696 91
At least 2 66 9
Serum LDH level (838)
Normal 696 83
Above upper normal limit 142 17
Serum albumin level (676)
Greater than 3 g/dL 646 96
No more than 3 g/dL 30 4
Hemoglobin (823)
At least 12 g/dL (10 g/dL for w) 757 92
Less than 12 g/dL (10 g/dL for w) 66 8
ESR (772)
Less than 30 mm 627 81
At least 30 mm 145 19
International Prognostic Index (649)
Low risk 369 57
Low intermediate risk 196 30
High intermediate risk 65 10
High risk 19 3
Table 2. Survival rates according to patient characteristics
Characteristic 5 Year 10 Year P Value
Age ,.0001
No more than 60 years 86 69
Greater than 60 years 61 38
Sex .0025
Female 80 64
Male 72 49
Ann Arbor stage ,.0001
I-II 89 84
III-IV 73 49
No. of extranodal sites .0494
0-1 77 58
Greater than or equal to 2 68 47
BM involvement .0001
Absent 85 72
Present 73 46
Bulky disease .8070
Absent 80 59
Present 75 65
B Symptoms ,.0001
Absent 80 61
Present 59 40
Performance status (ECOG) ,.0001
0-1 78 56
2-3 54 19
Serum LDH level .0002
Normal 82 60
Above upper normal limit 62 59
Serum albumin level .0086
Greater than 3 g/dL 83 65
No more than 3 g/dL 64 54
Hemoglobin .0001
At least 12 g/dL (10 g/dL for w) 83 65
Less than 12 g/dL (10 g/dL for w) 60 53
ESR ,.0001
Less than 30 mm 85 68
At least 30 mm 67 52
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at high risk (P not significant). The 5-year FFS of patients in CR
after initial therapy was 59% for patients at low risk, 50% for
patients at intermediate risk, and 23% for patients at high risk
(log-rank test, 28.95; P , .0001).
The predictive model developed for aggressive non-Hodgkin’s
lymphoma was able to stratify the same 429 patients in 3 different
risk groups: score 0-1, low risk, 264 patients; score 2, intermediate
risk, 120 patients; score 3-5, high risk, 45 patients. The 5- and
10-year survival rates were 89% and 70%, respectively, in the
low-risk group; 71% and 49% in the intermediate-risk group; and
47% and 8% in the high-risk group (log-rank test, 55.61; P , .0001)
(Figure 2B). As shown in Table 5, 293 patients (69%) were
allocated in the same risk group using both indexes; 70 patients
(16%) with our model were placed into a higher risk group, and 66
patients (15%) with the IPI were placed into a higher risk group. No
statistically significant differences in survival were observed be-
tween groups of patients placed into higher risk groups with either
model (log-rank test, 0.17; P 5 .57). According to our predictive
model, 17 out of 429 patients (4.0%) who were 60 years of age or
younger were at high risk, while only 7 patients (1.6%) were at high
risk according to the IPI.
Validation sample
The outcome of 429 patients with complete data was similar to the
outcome of the 559 patients with incomplete data (log-rank test,
1.50; P 5 .2204). As a result, we used the latter group as the source
to identify a validation sample for our model. Out of the 559
patients with incomplete data, we found 265 patients with complete
data for the 6 variables used in the development of our predictive
model, and we selected all of them as a validation sample. The
predictive model was also able to stratify this group of patients into
3 risk groups with statistically significant different outcomes
(Figure 3A). The 5- and 10-year survival rates were 95% and 87%,
respectively, in the low-risk group; 77% and 73% in the intermedi-
ate-risk group; and 62% and 62% in the high-risk group (log-rank
test, 17.7; P 5 .0001).
As in the training sample, no differences in the 5-year RFS were
observed among patients at different risks according to our model.
However, the 5-year FFS was 60% for low-risk patients, 56% for
intermediate-risk patients, and 36% for high-risk patient (log-rank
test, 6.02; P 5 .0494).
Moreover, the model was also predictive for 210 patients from
the validation sample who were uniformly treated with doxorubicin-
containing regimens (Figure 3B). The 5- and 10-year survival rates
for low-risk patients were 98% and 91%, respectively, and 86% and
79% for intermediate-risk patients. High-risk patients had a 5-year
survival of 62% (P 5 .0001), and it was not possible to assess the
survival rate at 10 years because no patient in the high-risk group
had a follow-up period beyond 8 years.
Figure 2. Survival in the training sample. Survival rates are given according to (A)
the prognostic model developed by the Intergruppo Italiano Linfomi and (B) the IPI.
Table 3. Factors with independent prognostic value of survival
in the training sample
Factor
Relative
Risk of Death
95%
CI
P
Value
Age (no more than 60 vs greater than 60) 2.6 1.6-4.1 ,.0001
Sex (F vs M) 1.8 1.2-2.8 .0079
Extranodal sites (0-1 vs at least 2) 2.1 1.0-4.2 .0445
Serum LDH (normal vs elevated) 2.0 1.2-3.5 .0074
B symptoms (absent vs present) 2.2 1.2-4.1 .0128
ESR (less than 30 vs at least 30) 2.4 1.5-4.1 .0006
Table 4. Outcome of 429 patients selected in the training sample according to
the number of presenting risk factors
No. of Risk
Factors No. of Cases No. of Deaths % Censored
% 5-Year
Survival
0 86 5 94 97
1 188 32 83 87
2 97 22 77 75
3 43 20 53 49
4 11 8 27 14
5 3 3 0 0
For 5-year survival, log-rank test, 128, 76; P , .0001.
Table 5. Distribution of the 429 patients included in the training sample
ILI
Model
IPI Model Total
CasesL I H
L 216 52 6 274
I 44 46 8 98
H 4 22 31 57
264 120 45 429
Figures given are according to the IPI and the prognostic model proposed by the
Italian Lymphoma Intergroup.
L indicates low risk (score 0-1); I indicates intermediate risk (score 2); and H
indicates high risk (score 3-5).
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Discussion
This report covered a very large series of patients with follicular
lymphoma, by far the largest ever studied, and provides definite
information on the outcome of patients diagnosed in several
institutions between 1985 and 1996 and treated with conventional
approaches. As previously shown, the outcome of our study
population was characterized by a 10-year overall survival of 57%,
RFS of 43%, and FFS of 30% and is comparable to that reported by
several other studies.2-6
The aim of this study was to analyze clinical variables in a large
number of cases and to explore the possibility of better predicting
the outcome of these patients. Among the several endpoints that
can be studied in prognostic analyses, we measured the outcome in
terms of remission rates, RFS, FFS, and overall survival. However,
according to Coiffier et al,13 it is difficult to assess CR in follicular
lymphoma because of possible minimal BM involvement. Thus,
CR and duration of remission do not seem the most reliable
endpoints for studying the prognosis of patients with follicular
lymphoma. For this reason, although we analyzed remission rates,
RFS, FFS, and overall survival, our prognostic model was based on
the analysis of overall survival.
In the literature, many prognostic factors have been shown to
predict a poor survival in follicular lymphoma. They include older
age, number of extranodal sites, high tumor burden, BM involve-
ment, bulky disease, B symptoms, poor PS, high LDH or b2-
microglobulin levels, anemia, and gut involvement.10-14
In order to better predict survival rates, we investigated several
pretreatment clinical features that are considered important predic-
tors of outcome, namely those recognized by the IPI. However, we
also looked for clinical features different from those considered in
the IPI model. These features included albumin level and ESR.
Unfortunately we were not able to assess the prognostic role of
b2-microglobulin because this information was lacking in most
cases.
A few patients had a serum albumin level less than 30 mmol/L,
and they did poorly. A low serum albumin level has proved to be a
poor prognostic factor in other lymphomas, like Hodgkin’s dis-
ease.23 In some cases hypoalbuminemia may reflect a deficient
caloric intake, intestinal protein loss, or liver damage, but in most
instances a linkage with tumor mass itself must be sought.23 BM
involvement, present in 52% of our patients, was linked to a poorer
survival. Romaguera et al17 found a significant correlation between
the degree of BM involvement (more than 20%) and survival.
Other studies did not show survival differences between patients
with or without BM involvement.24,25 In our series, patients with B
symptoms or low hemoglobin level also had shorter survival times,
as reported in other studies.16,18 Patients with an ESR greater than
30 mm had significantly poorer survival than patients with a normal
ESR. This feature has not been previously reported as a poor
prognostic factor in follicular lymphoma. However, this observa-
tion has already been described in other types of lymphomas26 and
can be related to an increased secretion of interleukins or tumor
necrosis factor (TNF). Finally, female sex was associated with a
better outcome. This fact is not easy to explain, but it has been
observed by others.17
When all 11 clinical features that were significant in univariate
analysis were considered, a multivariate regression analysis with
survival as the endpoint identified 6 key features of independent
importance: age, sex, B symptoms, number of extranodal sites,
LDH level, and ESR. These 6 independent variables defined a
prognostic model with 3 risk groups. Patients with no or 1
unfavorable variable were considered to be at low risk, those with 2
unfavorable variables were at intermediate risk, those with 3 or
more unfavorable variables were at high risk. These 3 risk groups
had different 5-year survival rates: score 0-1 (low risk), 90%; score
2 (intermediate risk), 75%; and score 3 (high risk), 38%. This
model was developed from the 429 patients for whom all 11
prognostic variables were available, and it was validated on an
independent cohort of 265 patients who had all 6 variables used in
the development of the model available for analysis. Moreover, the
model was also predictive in the group of 210 patients from the
validation sample who were uniformly treated with doxorubicin-
containing regimens.
Before the introduction of the IPI, the design of predictive
models was based on some of these features; however, they were
not widely accepted, perhaps because they were derived from a
limited number of cases and sometimes were difficult to apply.16-18
The IPI, originally devised for aggressive lymphomas, is simple to
use but has been applied in follicular lymphomas with contradic-
tory results. Moreover, the IPI has a limited discriminating power
because most patients are allocated in the favorable or intermediate
risk groups. In a study by Lopez-Guillermo et al19 performed on
Figure 3. Survival in the validation sample. Survival rates are given according to
the prognostic model developed by the ILI for (A) all 265 patients and (B) 210 patients
uniformly treated with doxorubicin-containing regimens.
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125 patients with low-grade lymphoma, the IPI identified 20.8% of
the patients at intermediate-high risk and 11.2% at high risk.
However, Lopez-Guillermo et al19 reported no differences in the
outcomes among patients at low-intermediate or high-intermediate
risk, and they were merged into 1 intermediate group. When the IPI
was applied in our series of patients, this model was able to
discriminate 3 risk groups with statistically different survival rates
(Figure 2B). As in other reports, the percentage of patients
allocated in the intermediate-high or high-risk group is quite low
(13%), and the IPI applied to our population of patients was useful
in predicting response and survival, but given the size of the study
population, this result is not surprising.
We believe that the prognostic model developed by the Inter-
gruppo Italiano Linfomi and based on the analysis of several
hundred patients with follicular lymphoma can be considered a step
forward in the study of the prognosis of these patients. In addition
to age, number of extranodal sites of involvement, and serum LDH
level, variables already recognized as important predictors by the
IPI, our study found that the prognosis of patients with follicular
lymphoma depends also on the presence of B symptoms or elevated
ESR. In patients with follicular lymphoma, these latter 2 param-
eters probably assume more important prognostic value than the
poor performance status itself. Additional advantages of our model
over the IPI are the remarkably higher discriminating power among
groups (log-rank test, 86.62 versus 55.61 for the IPI) and the ability
to identify a higher number of patients less than 60 years old with a
poor outcome (4.0% versus 1.6%), which will help determine
aggressive or innovative therapeutic approaches.
In recent years new therapeutic approaches have been investi-
gated in follicular lymphoma. These include myeloablative treat-
ment with stem cell rescue, purine analogues, and immunologic
therapy with anti-CD20 monoclonal antibodies.27-32 Some therapeu-
tic approaches result in not only complete clinical remission but
also molecular remission in most patients. Patients who obtain
molecular remission (disappearance of bcl-2 or immunoglobulin
gene rearrangements) are likely to have a prolonged survival and
RFS, and they may be cured of their lymphoma.33,34 However,
t(14;18)–containing cells have been detected in the peripheral
blood of patients who have been in remission for a number of years,
which indicates that a positive result may not have absolute
prognostic significance.35 High-dose therapy followed by hemopoi-
etic stem cell support increases the number of complete remissions,
but it is too early to draw any conclusions regarding the effect of
this approach on survival. Thus, in follicular lymphoma, a reliable
prognostic index would be useful in order to identify patients at
different risks of failure and to select those who might benefit from
new therapeutic approaches.
The score system proposed in this study identifies 3 risk groups
with statistically significant differences in outcome. Patients at low
risk had a very long survival and did fairly well with conventional
treatment. Patients at intermediate risk had a relatively good 5-year
survival but a reduced RFS, with a continuous pattern of relapse
and no suggestion of cure. In these patients the above-mentioned
new promising approaches can rationally be tested in randomized
trials. Finally, patients at high risk fared very poorly, with low CR
rates, high incidence of early relapse, and short median survival.
This group of patients needs to be treated with innovative
approaches early.
In conclusion, our model uses simple clinical characteristics,
usually collected at the time of diagnosis. It separates groups of
patients with substantially different outcomes. It may be useful to
tailor the therapy for the individual patient or to design prospective
randomized trials. Combining our model with other prognostic
variables, such as b2-microglobulin level or functional and molecu-
lar unfavorable factors (p-53, bcl-2, bcl-xL, CDK family, sCD23,
TNF, and vascular endothelial growth factor),36-38 may improve the
model’s discriminating power and identify more precisely those
patients with a poor prognosis who are suitable for innovative
approaches.
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Appendix
Participating institutions and principal investigators of the Intergruppo
Italiano Linfomi on follicular lymphoma include the following:
Gruppo Italiano Studio Linfomi [Oncologia Medica, Universita`
di Modena (V. Silingardi, M. Federico, V. Clo’); Dipartimento di
Emato-Oncologia, Azienda Ospedaliera Bianchi-Melacrino-
Morelli, Reggio Calabria (F. Nobile, M. Brugiatelli, V. Callea);
Cattedra di Ematologia, Universita` di Milano (M.T. Maiolo, L.
Baldini, M. Colombi); Divisione Medicina Ia, Sezione di Ematolo-
gia, Osp. Civile, Piacenza (L. Cavanna, D. Vallisa, R. Berte`);
Medicina Interna, Oncologia Medica, Universita` di Pavia (E.
Ascari, P.G. Gobbi, C. Pieresca); Servizio di Ematologia, Arcisped-
ale S.Maria Nuova Reggio Emilia (L. Gugliotta, P. Avanzini, F.
Merli); Dipartimento di Ematologia e Oncologia, USL di Pescara
(M. Lombardo, F. Angrilli); Divisione di Ematologia, Ospedale A.
Pugliese-Ciaccio, Catanzaro (S. Molica, M.G. Kropp); Istituto di
Ematologia, Universita` di Messina (V. Pitini); Divisione di Emato-
logia, IRCCS Casa Sollievo della Sofferenza, San Giovanni
Rotondo (M. Carotenuto, N. Di Renzo); Clinica Medica Ia,
Universita` di Modena (S. Sacchi, G. Longo); Divisione di Ematolo-
gia, Universita` di Modena (G. Torelli)]; U.O.A. Ematologia,
Azienda Ospedaliera San Giovanni Battista, Torino (E. Gallo, U.
Vitolo, C. Boccomini,); Istituto di Ematologia e Oncologia Medica
L&A Sera`gnoli, Universita` di Bologna (S. Tura, P.L. Zinzani);
Divisione di Ematologia, Ospedale Civile Venezia-Mestre (T.
Chisesi); Cattedra e Divisione di Ematologia, Universita` di Firenze
(P.L. Rossi Ferrini, G. Bellesi, R. Alterini); Clinica Medica
Generale, Policlinico Monteluce, Perugia (F. Grignani, M. Libe-
rati); Dipartimento di Biotecnologie Cellulari ed Ematologia,
Universita` La Sapienza, Roma (F. Mandelli, G. Avvisati, M.
Martelli); Ematologia Universitaria Tor Vergata, Roma (A. Per-
rotti); Dipartimento di Ematologia, Ospedale Santa Maria Goretti,
Latina (F. Ciccone, A. Chiericini); Dipartimento di Ematologia,
Ospedale San Giacomo, Roma (A. Andriani); Cattedra e Servizio
di Ematologia, Azienda Ospedaliera Policlinico, Bari (V. Liso, V.
Pavone, A. Guarini); Dipartimento di Scienze Biomediche, Sezione
di Ematologia, Universita` di Ferrara (G.L. Castoldi, A. Cuneo); and
Divisione di Ematologia Ia, Ospedale San Martino, Genova (G.
Santini, E.E. Damasio).
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